Hyaluronic Acid Derivatives — Clinical Coverage Guidance for Knee Osteoarthritis
Customize your policy alerts
Sign up for all quartz policy alerts
Know when quartz releases new policies or updates existing guidance.
Monitor payer policy activity
Clinical coverage guidance for intraarticular hyaluronic acid derivative products used to treat knee osteoarthritis for Quartz members; indicates which products require prior authorization and sets medical necessity criteria and dosing. Affects ordering/administration by physicians in rheumatology, orthopedics, and physical medicine/rehabilitation.
No material clinical or coverage changes in this revision.
Coverage Criteria for Hyaluronic Acid Injections (Knee)
Initial therapy coverage criteria
Covered when ALL of the following are met for osteoarthritis of the knee — Initial Therapy
Retreatment coverage criteria
Covered when ALL of the following are met for retreatment after prior hyaluronic acid course
Hyaluronic acid derivative injections are not recommended for acute ankle sprain or for pathologic conditions of joints other than the knee. Trials and guideline reviews do not support routine use in these situations and additional data are needed to determine benefit. Specifically, intraarticular HA products are not recommended for acute ankle sprain and have not been established for other non‑knee joint pathologies.
These agents are indicated for knee osteoarthritis only; they are not appropriate for other knee conditions such as chondromalacia patellae, osteochondritis dissecans, patellofemoral syndrome, or post‑ACL reconstruction because adequate, well‑designed trials have not established benefit in those disorders.
Use of intraarticular hyaluronic acid injections for joints other than the knee is considered unsupported by evidence and is not recommended. The prescribing information notes that safety and effectiveness have not been established for non‑knee joints, and professional guidelines (ACR/OARSI) do not recommend HA for hip or hand osteoarthritis.
Small trials in other joints (e.g., ankle, shoulder, hip) are inconclusive and do not provide sufficient evidence to support routine use; therefore requests for HA injections outside the knee will generally be subject to medical necessity review and may be denied absent supporting data.
Provider Requirements, Prior Authorization, and Documentation
Prior authorization requirement for HA products
Euflexxa, Synvisc, and Synvisc One are covered without prior authorization; all other named hyaluronic acid products are not covered unless a medical necessity review is completed.
Required conservative therapy steps before initial HA
Before initial intraarticular hyaluronic acid therapy for knee osteoarthritis, the patient must have radiographic confirmation of knee OA and must have tried specified conservative therapies.
- Radiologic evidence of knee osteoarthritis (examples: x‑ray, MRI, CT, ultrasound).
- At least one course of physical therapy for knee osteoarthritis.
- At least two pharmacologic therapies (oral or topical NSAID(s), acetaminophen, tramadol, or duloxetine); a trial of two or more NSAIDs (oral and/or topical) counts as one.
- At least two intraarticular corticosteroid injections to the affected knee.
- Product must be administered by or under the supervision of a physician in rheumatology, orthopedic surgery, or physical medicine and rehabilitation (physiatrist).
Required clinical documentation for initial therapy
Clinical documentation submitted for initial hyaluronic acid therapy must confirm radiologic evidence of knee osteoarthritis, prior conservative therapy trials, and physician specialty supervision of the injection.
- Documentation of radiographic confirmation (x‑ray, MRI, CT, or ultrasound) of the knee to be treated.
- Records showing trials of the required conservative therapies: physical therapy, at least two pharmacologic agents (NSAID(s), acetaminophen, tramadol, or duloxetine), and at least two intraarticular corticosteroid injections.
- Documentation that the product will be administered by or under the supervision of a physician specializing in rheumatology, orthopedic surgery, or physical medicine and rehabilitation.
Not‑covered HA products require medical necessity review
Requests for products listed as not covered will trigger a medical necessity review and may be denied if documentation does not support coverage.
- Products listed as not covered include Durolane, Gel‑One, Gelsyn‑3, GenVisc 850, Hyalgan, Hymovis, Monovisc, Orthovisc, Supartz FX, sodium hyaluronate 1%, Synojoynt, Triluron, TriVisc, Visco‑3.
- If coverage is requested for these products, a medical necessity review will be completed and the request may be denied if criteria are not met.
Background
Hyaluronic acid (HA) derivatives are intraarticular injectable preparations intended to restore the normal viscoelastic properties (viscosity and elasticity) of synovial fluid and are indicated for the treatment of pain related to knee osteoarthritis in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics.
Products include both avian‑derived (e.g., Gel‑One, Hyalgan, Supartz FX, Synvisc/Synvisc‑One) and nonavian preparations; dosing regimens vary by product (from single‑injection to five‑injection courses), and retreatment data are limited but often require a minimum interval of 6 months before repeat courses.
Definitions and Guideline Context
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.